Fatma Yurt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fatma Yurt has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
- Kasim Ocakoglu
Tarsus University
19 shared publications Ayça Tunçel
13 shared publicationsDerya Özel
Institute of Nuclear Sciences, Department of Nuclear Applications, Ege University, Bornova, 35100 Izmir, Turkey
12 shared publicationsOzge Er
Department of Nuclear Applications, Institute of Nuclear Science, Ege University, Bornova, 35100, Izmir, Izmir, Turkey
12 shared publications- Ayça Tunçel
Institute of Nuclear Science, Department of Nuclear Applications, Ege University, Bornova, 35100, Izmir, Turkey
9 shared publications Osman Yilmaz
Institute of Health Sciences, Department of Laboratory Animals
9 shared publications
Latest Publications
- Open Access
- 22 June 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (26) , 38684-38694
Evaluation of 89 Zr-DFO Functionalized Manganese–Iron Oxide Core–Shell Nanoparticles as a HER2-Targeted Multimodal Imaging Candidate Nanoplatform
Hybrid multimodal imaging agents combining magnetic resonance imaging (MRI) and positron emission tomography (PET) capabilities offer potential for accurate tumor detection and monitoring. In our previous study, we synthesized manganese-loaded, mesoporous silica-coated superparamagnetic iron oxide nanoparticles functionalized with trastuzumab (Fe3O4-mSi-NH2-Mn-Tra), which demonstrated dual T1/T2 MRI contrast enhancement and selective cytotoxicity against HER2-positive breast cancer cells in vitro. In the current study, the nanoparticle was labeled with Zirconium-89 (89Zr) to evaluate its potential as a HER2-targeted PET imaging agent- candidate. Radiolabeling was performed using the p-isothiocyanatobenzyl-desferrioxamine (p-NCS-Bz-DFO) chelator, 89Zr-DFO-Fe3O4-mSi-NH2-Mn-Tra was labeled of 78 ± 2%. The labeled nanoparticles demonstrated high colloidal stability in PBS for up to 24 h and lipophilic (log P = 2.23 ± 0.24). In in vitro uptake studies, radiolabeled nanoparticles showed receptor-specific internalization in HER2-positive SKBR-3 cells (65.25% at 2 h), whereas the uptake was limited in HER2-negative MDA-MB-231 cells (20.22% at 4 h). When the receptor was blocked with trastuzumab, the uptake results was reduced by 11.14 ± 1.2%, confirming HER2-mediated binding. In vivo biodistribution studies in rats have shown that the radiolabeled nanoparticles accumulate in the reticuloendothelial organs (liver 15.53 ± 7.6% ID/g at 120 min) and renal excretion. These results suggest that 89Zr-DFO-Fe3O4-mSi-NH2-Mn-Tra nanoparticles may serve as a promising HER2-targeted PET/MRI candidate nanoplatform for further preclinical evaluation.
- 22 June 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (26) , 38684-38694
Open AccessEvaluation of 89 Zr-DFO Functionalized Manganese–Iron Oxide Core–Shell Nanoparticles as a HER2-Targeted Multimodal Imaging Candidate Nanoplatform
Hybrid multimodal imaging agents combining magnetic resonance imaging (MRI) and positron emission tomography (PET) capabilities offer potential for accurate tumor detection and monitoring. In our previous study, we synthesized manganese-loaded, mesoporous silica-coated superparamagnetic iron oxide nanoparticles functionalized with trastuzumab (Fe3O4-mSi-NH2-Mn-Tra), which demonstrated dual T1/T2 MRI contrast enhancement and selective cytotoxicity against HER2-positive breast cancer cells in vitro. In the current study, the nanoparticle was labeled with Zirconium-89 (89Zr) to evaluate its potential as a HER2-targeted PET imaging agent- candidate. Radiolabeling was performed using the p-isothiocyanatobenzyl-desferrioxamine (p-NCS-Bz-DFO) chelator, 89Zr-DFO-Fe3O4-mSi-NH2-Mn-Tra was labeled of 78 ± 2%. The labeled nanoparticles demonstrated high colloidal stability in PBS for up to 24 h and lipophilic (log P = 2.23 ± 0.24). In in vitro uptake studies, radiolabeled nanoparticles showed receptor-specific internalization in HER2-positive SKBR-3 cells (65.25% at 2 h), whereas the uptake was limited in HER2-negative MDA-MB-231 cells (20.22% at 4 h). When the receptor was blocked with trastuzumab, the uptake results was reduced by 11.14 ± 1.2%, confirming HER2-mediated binding. In vivo biodistribution studies in rats have shown that the radiolabeled nanoparticles accumulate in the reticuloendothelial organs (liver 15.53 ± 7.6% ID/g at 120 min) and renal excretion. These results suggest that 89Zr-DFO-Fe3O4-mSi-NH2-Mn-Tra nanoparticles may serve as a promising HER2-targeted PET/MRI candidate nanoplatform for further preclinical evaluation.
- Open Access
- 10 April 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (4) , 411
Synthesis and Biocompatibility of Carboplatin-Loaded PEG-PLGA Nanoparticles for Mesenchymal Stem Cell-Mediated Cancer Therapy
Purpose: Biocompatibility is a critical requirement for nanoparticle-loaded mesenchymal stem cells (MSCs) used in targeted cancer therapy. This study aimed to evaluate the compatibility of carboplatin-loaded PEG–PLGA nanoparticles (CRB@PEG–PLGA) with adipose tissue-derived mesenchymal stem cells (ADSCs). Methods: CRB@PEG–PLGA nanoparticles were synthesized using a double emulsion solvent evaporation method and characterized by dynamic light scattering (DLS), Fourier-transform infrared spectroscopy (FT-IR), and scanning electron microscopy (SEM). Isolated ADSCs were validated by surface marker expression and differentiation assays. Nanoparticle size, zeta potential, encapsulation efficiency (EE), and drug loading capacity (LC) were determined. Biocompatibility was assessed using a 24-hour MTT assay at increasing concentrations up to 7000 ng/mL. Results: The nanoparticles exhibited a mean hydrodynamic diameter of 181.3 ± 9.07 nm, a zeta potential of − 14.1 ± 0.71 mV, an encapsulation efficiency of 66.4 ± 3.6%, and a drug loading capacity of 16.5 ± 5.8%. In vitro cytotoxicity analysis demonstrated that ADSCs treated with CRB@PEG–PLGA maintained approximately 64.86% viability at the highest tested concentration, showing significantly improved biocompatibility compared to free carboplatin. Drug-free PEG–PLGA nanoparticles exhibited minimal cytotoxicity. Conclusion: CRB@PEG–PLGA nanoparticles demonstrate favorable physicochemical properties and acceptable biocompatibility with ADSCs, supporting their potential application as a carrier platform in MSC-based targeted cancer therapy.
- 10 April 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (4) , 411
Open AccessSynthesis and Biocompatibility of Carboplatin-Loaded PEG-PLGA Nanoparticles for Mesenchymal Stem Cell-Mediated Cancer Therapy
Purpose: Biocompatibility is a critical requirement for nanoparticle-loaded mesenchymal stem cells (MSCs) used in targeted cancer therapy. This study aimed to evaluate the compatibility of carboplatin-loaded PEG–PLGA nanoparticles (CRB@PEG–PLGA) with adipose tissue-derived mesenchymal stem cells (ADSCs). Methods: CRB@PEG–PLGA nanoparticles were synthesized using a double emulsion solvent evaporation method and characterized by dynamic light scattering (DLS), Fourier-transform infrared spectroscopy (FT-IR), and scanning electron microscopy (SEM). Isolated ADSCs were validated by surface marker expression and differentiation assays. Nanoparticle size, zeta potential, encapsulation efficiency (EE), and drug loading capacity (LC) were determined. Biocompatibility was assessed using a 24-hour MTT assay at increasing concentrations up to 7000 ng/mL. Results: The nanoparticles exhibited a mean hydrodynamic diameter of 181.3 ± 9.07 nm, a zeta potential of − 14.1 ± 0.71 mV, an encapsulation efficiency of 66.4 ± 3.6%, and a drug loading capacity of 16.5 ± 5.8%. In vitro cytotoxicity analysis demonstrated that ADSCs treated with CRB@PEG–PLGA maintained approximately 64.86% viability at the highest tested concentration, showing significantly improved biocompatibility compared to free carboplatin. Drug-free PEG–PLGA nanoparticles exhibited minimal cytotoxicity. Conclusion: CRB@PEG–PLGA nanoparticles demonstrate favorable physicochemical properties and acceptable biocompatibility with ADSCs, supporting their potential application as a carrier platform in MSC-based targeted cancer therapy.
- 22 December 2025
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 50 (2) , 1125-1138
Novel Schiff base-Pt( ii ) complexes: inhibition of Aβ aggregation via histidine interaction
Three novel Schiff base–Pt( ii ) complexes were synthesized and characterized. Complexes I and III showed significant anti-amyloid activity by inhibiting Aβ 1–42 peptide aggregation in vitro , with potential to cross the blood–brain barrier.
- 22 December 2025
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 50 (2) , 1125-1138
Novel Schiff base-Pt( ii ) complexes: inhibition of Aβ aggregation via histidine interaction
Three novel Schiff base–Pt( ii ) complexes were synthesized and characterized. Complexes I and III showed significant anti-amyloid activity by inhibiting Aβ 1–42 peptide aggregation in vitro , with potential to cross the blood–brain barrier.
- 27 November 2025
- Published by Taylor & Francis in Nanomedicine
- Vol. 21 (2) , 195-211
Evaluation of PTX/Mo 2 CTx-MXene@Fuc surface-engineered nanosheets in targeted combination therapy for triple-negative breast cancer
The study aimed to evaluate the multifunctional therapeutic potential of PTX/Mo2CTx-MXene@Fuc combinations, emphasizing their performance in drug loading, release kinetics, oxidative stress induction, apoptosis, cell migration, and angiogenesis inhibition in cancer therapy. Mo2CTx-MXene@Fuc were synthesized and loaded with the chemotherapeutic drug Paclitaxel (PTX) to achieve pH- and NIR-responsive release. In vitro cytotoxicity, ROS generation, apoptosis, migration, and tube-formation assays were performed on cancer (4T1, MDA-MB-231) and normal (L929) cell lines under NIR (808 nm) irradiation. The nanosheets exhibited high PTX loading efficiency (85-90%) and pH-sensitive drug release, with accelerated release in acidic tumor-mimicking environments. NIR irradiation significantly enhanced ROS production in cancer cells while maintaining low oxidative activity in normal cells. Apoptosis assays confirmed pronounced cell death under NIR+ conditions, while migration and tube-formation analyses revealed that MXene nanosheets moderately inhibited cell motility and suppressed endothelial angiogenesis. These results demonstrated synergistic enhancement of photothermal, photodynamic, and chemotherapeutic effects. The findings indicate that PTX/Mo2CTx-MXene@Fuc nanosheets function as a multifunctional nanoplatform combining chemo-, photothermal-, and photodynamic-therapy mechanisms. Their selective cytotoxicity, ROS-mediated apoptosis, and anti-angiogenic activity highlight their strong potential for future targeted cancer therapy applications.
- 27 November 2025
- Published by Taylor & Francis in Nanomedicine
- Vol. 21 (2) , 195-211
Evaluation of PTX/Mo 2 CTx-MXene@Fuc surface-engineered nanosheets in targeted combination therapy for triple-negative breast cancer
The study aimed to evaluate the multifunctional therapeutic potential of PTX/Mo2CTx-MXene@Fuc combinations, emphasizing their performance in drug loading, release kinetics, oxidative stress induction, apoptosis, cell migration, and angiogenesis inhibition in cancer therapy. Mo2CTx-MXene@Fuc were synthesized and loaded with the chemotherapeutic drug Paclitaxel (PTX) to achieve pH- and NIR-responsive release. In vitro cytotoxicity, ROS generation, apoptosis, migration, and tube-formation assays were performed on cancer (4T1, MDA-MB-231) and normal (L929) cell lines under NIR (808 nm) irradiation. The nanosheets exhibited high PTX loading efficiency (85-90%) and pH-sensitive drug release, with accelerated release in acidic tumor-mimicking environments. NIR irradiation significantly enhanced ROS production in cancer cells while maintaining low oxidative activity in normal cells. Apoptosis assays confirmed pronounced cell death under NIR+ conditions, while migration and tube-formation analyses revealed that MXene nanosheets moderately inhibited cell motility and suppressed endothelial angiogenesis. These results demonstrated synergistic enhancement of photothermal, photodynamic, and chemotherapeutic effects. The findings indicate that PTX/Mo2CTx-MXene@Fuc nanosheets function as a multifunctional nanoplatform combining chemo-, photothermal-, and photodynamic-therapy mechanisms. Their selective cytotoxicity, ROS-mediated apoptosis, and anti-angiogenic activity highlight their strong potential for future targeted cancer therapy applications.
- 7 November 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (46) , 63069-63088
Tri-Modal Anticancer Therapy via Mo 2 C-MXene-Based Hybrid Nanostructures: A Synergistic Strategy Against Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is an aggressive tumor subtype that is resistant to conventional therapies due to the lack of targetable receptors. In this study, a paclitaxel (PTX)-loaded Mo2C@C@Fuc/Mo2C-MXene@Fuc hybrid nanosystem was developed, and the efficacy of a combined therapeutic approach, photothermal therapy (PTT), photodynamic therapy (PDT), and chemotherapy (CT) was evaluated in vitro and in vivo against TNBC. The PTX/Mo2C@C@Fuc/Mo2C-MXene@Fuc hybrid nanosystem exhibited high drug loading efficiency and stimuli-responsive release. At 96 h, PTX release reached 58.6% at pH 4.5 and 44.2% at pH 6.0, while NIR irradiation further enhanced the release to 66.3% and 51.0%, respectively, confirming the pH- and light-responsive drug delivery capability of the system. Under NIR irradiation (808 nm), the hybrid structure generated significant levels of reactive oxygen species (ROS), leading to pronounced apoptotic induction and reducing cell viability to 52.8% in 4T1 cells. Similarly, in MDA-MB-231 cells, NIR-assisted combination treatment decreased viability to 55.9%. In contrast, L929 normal fibroblast cells retained a viability of 75.4% under the same treatment conditions, indicating cytotoxicity. Tube formation assay results demonstrated that the hybrid system significantly inhibited vascular structure formation in HUVEC cells after 24 h of incubation. In vivo studies further confirmed that the PTX-loaded hybrid system combined with NIR irradiation induced 82% necrosis and 12.5% apoptosis within tumor tissues, ultimately resulting in complete macroscopic tumor regression. Overall, this study highlights the potential of Mo2C-MXene-based hybrid nanostructures as a biocompatible and therapeutic platform for synergistic PDT/PTT/CT combination therapy in TNBC treatment.
- 7 November 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (46) , 63069-63088
Tri-Modal Anticancer Therapy via Mo 2 C-MXene-Based Hybrid Nanostructures: A Synergistic Strategy Against Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is an aggressive tumor subtype that is resistant to conventional therapies due to the lack of targetable receptors. In this study, a paclitaxel (PTX)-loaded Mo2C@C@Fuc/Mo2C-MXene@Fuc hybrid nanosystem was developed, and the efficacy of a combined therapeutic approach, photothermal therapy (PTT), photodynamic therapy (PDT), and chemotherapy (CT) was evaluated in vitro and in vivo against TNBC. The PTX/Mo2C@C@Fuc/Mo2C-MXene@Fuc hybrid nanosystem exhibited high drug loading efficiency and stimuli-responsive release. At 96 h, PTX release reached 58.6% at pH 4.5 and 44.2% at pH 6.0, while NIR irradiation further enhanced the release to 66.3% and 51.0%, respectively, confirming the pH- and light-responsive drug delivery capability of the system. Under NIR irradiation (808 nm), the hybrid structure generated significant levels of reactive oxygen species (ROS), leading to pronounced apoptotic induction and reducing cell viability to 52.8% in 4T1 cells. Similarly, in MDA-MB-231 cells, NIR-assisted combination treatment decreased viability to 55.9%. In contrast, L929 normal fibroblast cells retained a viability of 75.4% under the same treatment conditions, indicating cytotoxicity. Tube formation assay results demonstrated that the hybrid system significantly inhibited vascular structure formation in HUVEC cells after 24 h of incubation. In vivo studies further confirmed that the PTX-loaded hybrid system combined with NIR irradiation induced 82% necrosis and 12.5% apoptosis within tumor tissues, ultimately resulting in complete macroscopic tumor regression. Overall, this study highlights the potential of Mo2C-MXene-based hybrid nanostructures as a biocompatible and therapeutic platform for synergistic PDT/PTT/CT combination therapy in TNBC treatment.
- 26 September 2025
- Published by Celal Bayar University Journal of Science in Celal Bayar Üniversitesi Fen Bilimleri Dergisi
- Vol. 21 (3) , 113-120
Investigation of In Vitro Cytotoxicity of Hypericum Perforatum in Pancreatic Cancer
Pancreatic cancer remains one of the most aggressive malignancies with poor prognosis and limited treatment options. In view of the constraints imposed by current treatment modalities, there has been an increased focus on natural products as potential complementary agents in cancer therapy. Hypericum perforatum (HP), commonly known as St. John’s Wort, has demonstrated cytotoxic and apoptotic properties in various cancer models; however, its effects on pancreatic cancer cells are not well-studied. This study aimed to investigate the in vitro cytotoxic effects of Hypericum perforatum extract on AR42J pancreatic cancer cells. AR42J cells were cultured and treated with increasing concentrations (3.125–100 µg/mL) of HP extract for 24 and 48 hours. Cell viability was assessed using the MTT assay. Nuclear morphological changes were evaluated by DAPI staining and visualized with a Juli™ Smart Fluorescent Cell Analyzer. HP extract exhibited a dose- and time-dependent cytotoxic effect on AR42J cells. IC₅₀ values were determined to be 12.5 µg/mL at 24 hours and 6.25 µg/mL at 48 hours. DAPI staining confirmed nuclear condensation and fragmentation in treated cells, supporting apoptosis as a mechanism of action. These results indicate that H. perforatum extract effectively reduced pancreatic cancer cell viability while inducing apoptotic cell death. These findings suggest that H.perforatum extract exerts significant antiproliferative and pro-apoptotic effects on AR42J pancreatic cancer cells. The study highlights its potential as a plant- based complementary therapeutic candidate for pancreatic cancer treatment.
- 26 September 2025
- Published by Celal Bayar University Journal of Science in Celal Bayar Üniversitesi Fen Bilimleri Dergisi
- Vol. 21 (3) , 113-120
Investigation of In Vitro Cytotoxicity of Hypericum Perforatum in Pancreatic Cancer
Pancreatic cancer remains one of the most aggressive malignancies with poor prognosis and limited treatment options. In view of the constraints imposed by current treatment modalities, there has been an increased focus on natural products as potential complementary agents in cancer therapy. Hypericum perforatum (HP), commonly known as St. John’s Wort, has demonstrated cytotoxic and apoptotic properties in various cancer models; however, its effects on pancreatic cancer cells are not well-studied. This study aimed to investigate the in vitro cytotoxic effects of Hypericum perforatum extract on AR42J pancreatic cancer cells. AR42J cells were cultured and treated with increasing concentrations (3.125–100 µg/mL) of HP extract for 24 and 48 hours. Cell viability was assessed using the MTT assay. Nuclear morphological changes were evaluated by DAPI staining and visualized with a Juli™ Smart Fluorescent Cell Analyzer. HP extract exhibited a dose- and time-dependent cytotoxic effect on AR42J cells. IC₅₀ values were determined to be 12.5 µg/mL at 24 hours and 6.25 µg/mL at 48 hours. DAPI staining confirmed nuclear condensation and fragmentation in treated cells, supporting apoptosis as a mechanism of action. These results indicate that H. perforatum extract effectively reduced pancreatic cancer cell viability while inducing apoptotic cell death. These findings suggest that H.perforatum extract exerts significant antiproliferative and pro-apoptotic effects on AR42J pancreatic cancer cells. The study highlights its potential as a plant- based complementary therapeutic candidate for pancreatic cancer treatment.
- 27 August 2025
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
Targeted Therapy for Glioblastoma: Synergistic Effects of GO/C-TMZ,@, PmAb and Magnetic Hyperthermia
This study investigates the therapeutic potential of a nanohybrid structure, GO/C-TMZ@PmAb MNP, for targeted glioblastoma treatment by integrating chemotherapy with magnetic hyperthermia. Characterization of the nanohybrid confirmed successful conjugation of Panitumumab (PmAb) and effective loading of Temozolomide (TMZ), ensuring targeted delivery to glioblastoma cells. In vitro experiments demonstrated enhanced cytotoxicity and a significant increase in late-stage apoptosis in U-87 MG and U-251 MG glioblastoma cell lines, particularly when combined with an alternating magnetic field (AMF), highlighting the synergistic effect of combined therapy. Cellular uptake studies via ICP-OES and fluorescence microscopy revealed maximum uptake at 6 h postincubation. In vivo studies using a subcutaneous U-251 MG tumor model showed substantial inhibition of tumor growth, increased necrosis, and apoptosis rates, as well as reduced EGFRvIII expression in treated groups. Notably, the GO/C-TMZ@PmAb + AMF group exhibited the greatest therapeutic effect, with controlled tumor growth and minimal systemic toxicity observed in healthy organs. These results underscore the efficacy of the GO/C-TMZ@PmAb MNP nanohybrid in enhancing glioblastoma treatment through targeted drug delivery and hyperthermia, providing a promising platform for further preclinical and clinical investigations.
- 27 August 2025
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
Targeted Therapy for Glioblastoma: Synergistic Effects of GO/C-TMZ,@, PmAb and Magnetic Hyperthermia
This study investigates the therapeutic potential of a nanohybrid structure, GO/C-TMZ@PmAb MNP, for targeted glioblastoma treatment by integrating chemotherapy with magnetic hyperthermia. Characterization of the nanohybrid confirmed successful conjugation of Panitumumab (PmAb) and effective loading of Temozolomide (TMZ), ensuring targeted delivery to glioblastoma cells. In vitro experiments demonstrated enhanced cytotoxicity and a significant increase in late-stage apoptosis in U-87 MG and U-251 MG glioblastoma cell lines, particularly when combined with an alternating magnetic field (AMF), highlighting the synergistic effect of combined therapy. Cellular uptake studies via ICP-OES and fluorescence microscopy revealed maximum uptake at 6 h postincubation. In vivo studies using a subcutaneous U-251 MG tumor model showed substantial inhibition of tumor growth, increased necrosis, and apoptosis rates, as well as reduced EGFRvIII expression in treated groups. Notably, the GO/C-TMZ@PmAb + AMF group exhibited the greatest therapeutic effect, with controlled tumor growth and minimal systemic toxicity observed in healthy organs. These results underscore the efficacy of the GO/C-TMZ@PmAb MNP nanohybrid in enhancing glioblastoma treatment through targeted drug delivery and hyperthermia, providing a promising platform for further preclinical and clinical investigations.
- 15 July 2025
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 334 (7) , 4571-4582
Preparation and biodistribution of [131I]iodoelmalienoside a, a saponin-based adjuvant, in mice
- 15 July 2025
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 334 (7) , 4571-4582
Preparation and biodistribution of [131I]iodoelmalienoside a, a saponin-based adjuvant, in mice